Ophir Shahaf

Ophir Shahaf was appointed to the position of Managing Director of Hadasit Bio-Holdings Ltd., the publicly traded subsidiary of Hadasit, upon its IPO in January 2006. He was promoted to the position of Chief Executive Officer in March 2007. Mr. Shahaf is responsible for all of the ongoing activities of the public entity, including financial, legal, IR/PR, investment and fundraising issues. Before this position, he served as Vice President, Business Development, at Protalix Biotherapeutics, a biopharmaceutical company focusing on the expression of human recombinant proteins in plant cell cultures. Mr. Shahaf was a part of the founding and management team of Clal Biotechnology Industries Ltd., Israel’s largest corporate investor in the life sciences, where he served as Vice President and General Counsel, and participated in the management and investment of more than $100 million. He received his law degree from Tel Aviv University, and his MBA from the Leonard N. Stern School of Business at New York University with a major in finance and international business. He teaches several courses in biotechnology entrepreneurship and management, and is a Fellow of the Merage Foundation at Irvine, Calif.